Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Nasopharyngeal Carcinoma 1Multiple Myeloma 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 51Gemcitabine 26toripalimab 20Radiotherapy, Intensity-Modulated 19Fluorouracil 16Capecitabine 16camrelizumab 15Docetaxel 14nimotuzumab 12Radiotherapy 10Drug Therapy 10apatinib 9Nivolumab 9sintilimab 8endostar protein 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Immune Checkpoint Inhibitors 7tislelizumab 6spartalizumab 6Chemoradiotherapy 6Cetuximab 6Bevacizumab 6pembrolizumab 5nedaplatin 5S 1 (combination) 5Radiation 5Paclitaxel 5Endostatins 5anlotinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Nasopharyngeal Carcinoma × Cell Count × Clear all
NCT03648697 2020-08-11

EBV-TCR-T(YT-E001)for Patients With EBV-positive Recurrent or Metastatic NPC

Fujian Cancer Hospital

Phase 2 Unknown
20 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡